Overview

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

Status:
Completed
Trial end date:
2012-10-05
Target enrollment:
Participant gender:
Summary
This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin. The purpose of this study is to compare infection-related hospital length of stay, along with a number of participant-reported outcomes, between participants with complicated skin and soft tissue infection treated with daptomycin and vancomycin.
Phase:
Phase 4
Details
Lead Sponsor:
Cubist Pharmaceuticals LLC
Treatments:
Anti-Bacterial Agents
Daptomycin
Methicillin
Vancomycin